ライフサイエンスコーパス: hematology

1 International Council for Standardization in Hematology.

2 ial has been an elusive goal of experimental hematology.

3 lonality often defines the diseased state in hematology.

4 ia is an important aspect of the practice of hematology.

5 a wide range of biologic systems, including hematology.

6 e most challenging and expensive problems in hematology.

7 quacy of dialysis, or serum biochemistry and hematology.

8 ) transcription factor family revolutionized hematology.

9 ne cell populations that matched traditional hematology.

10 uture prospects for genome editing to impact hematology.

11 rates as defined by the American Society of Hematology.

12 sis database maintained by the Department of Hematology.

13 new physicians to specialize in nonmalignant hematology.

14 ons that predominantly focus on nonmalignant hematology.

15 dress 'druggability' of new PPIs relevant to hematology.

16 es, coupled with principles of neurology and hematology.

17 nces in the science and clinical practice of hematology.

18 Blood Institute and the American Society of Hematology.

19 lood cell which is important in the field of hematology.

20 fulness of AMPSs in point-of-care diagnostic hematology.

21 review series on the role of epigenetics in hematology.

22 potential uses of this model in experimental hematology.

23 ctions of circulating miRNAs in the field of hematology.

24 te chromatin modification patterns to normal hematology.

25 ment guidelines from the American Society of Hematology (1996) and the British Committee for Standard

26 us diseases and AIDS (70%), and oncology and hematology (61.9%).

27 with risk organ involvement (liver, spleen, hematology), 68.6% of patients (35 of 51) with multisyst

28 follow-up measures of health markers (e.g., hematology/adipose biopsies).

29 Purpose: To update American Society of Hematology/American Society of Clinical Oncology recomme

30 otypic characterization included analysis of hematology, amino acid profiles, metabolism, and sudomot

31 In support of this, hematology analysis revealed that Nrf2(-/-) mice suffer

32 ptured by a high-throughput peroxidase-based hematology analyzer during performance of a complete blo

33 POC Hgb levels correlated with hematology analyzer Hgb levels (r = 0.864 and r = 0.856

34 varying degrees and etiologies and compared hematology analyzer Hgb levels with POC Hgb levels, whic

35 The CellaVision DM96 is a digital hematology analyzer that utilizes neural networks to loc

36 and venous blood samples using the standard hematology analyzer was high, with no clinically relevan

37 d a decent match to a commercially available hematology analyzer.

38 gram, and white blood cell (WBC) counts with hematology analyzer.

39 were measured and compared using a standard hematology analyzer.

40 Hematology analyzers evaluate CBCs by making high-dimens

41 Recently, several hematology analyzers have been developed to improve accu

42 Modern hematology analyzers provide additional data on the hete

43 Automated hematology analyzers were used to enumerate TNCs.

44 taken millions of times per day by clinical hematology analyzers, and they are important factors in

45 For that purpose, sophisticated automated hematology analyzers, microscopy, and bedside microfluid

46 typically measured from blood samples using hematology analyzers, which are housed in hospitals, cli

47 agreement with flow cytometry and automated hematology analyzers.

48 , and abstracts from the American Society of Hematology and American Society of Clinical Oncology pub

49 asurements of the mouse body and organ mass, hematology and biochemistry evaluation, and histopatholo

50 Hematology and blood biochemistry were unremarkable.

51 The American Society of Hematology and British Committee for Standards in Haemat

52 This review updates the American Society of Hematology and British guidelines on immune thrombocytop

53 gnostic and therapeutic insights relevant to hematology and cardiovascular medicine, and further adva

54 Length of stay; cost of care; costs of hematology and chemistry evaluation, pharmacy, and radio

55 taceans as it occurs prior to alterations in hematology and chemistry.

56 ignificant changes from baseline in selected hematology and clinical chemistry parameters.

57 Rabbits serum lipid profile, hematology and histology were investigated.

58 c exploration of single patients not only in hematology and immunology but also in other fields.

59 to learn, and cross-disciplinary studies in hematology and immunology will continue to pave the way

60 patient-centered, value-oriented approach in hematology and medical oncology.

61 S 2006 trial by Nordic Society for Pediatric Hematology and Oncology (NOPHO), Dutch Childhood Oncolog

62 ia (ALL) in Italian Association of Pediatric Hematology and Oncology Berlin-Frankfurt-Munster (AIEOP-

63 This Update in Hematology and Oncology features 16 articles published i

64 he US Food and Drug Administration Office of Hematology and Oncology Products in 2015.

65 Hematology and oncology specialists who refer patients t

66 y for research and training in nonneoplastic hematology and presents potential strategies for address

67 no patient did elevated HAMA titers develop, hematology and serum chemistry changes were clinically i

68 ples: to promote both the art and science of hematology and to hold a high-quality Educational Meetin

69 Clinical, hematology, and blood transfusion databases were linked

70 ory evaluations included serum biochemistry, hematology, and measurements of hemolytic antipig antibo

71 erts from the fields of immunology, allergy, hematology, and pathology contributed to this project.

72 f Clinical Oncology, the American Society of Hematology, and the Coalition of National Cancer Coopera

73 ty of Clinical Oncology, American Society of Hematology, and the International Myeloma Workshop.

74 hat had contributed so much to histology and hematology, and would soon contribute equally to experim

75 ia is one of the great successes of clinical hematology andoncology.

76 ents was reported at the American Society of Hematology Annual Meeting, 2012; the approach was feasib

77 collected on lipoprotein levels, hemostasis, hematology, anthropometry, blood pressure, medical histo

78 lementation of PRO assessment in the current hematology arena, by providing some real world examples

79 linic experience, visibility of nonmalignant hematology as a career path, and level of training progr

80 tter provides a snapshot of the evolution of hematology as a scientific and clinical discipline and t

81 alty, creating tensions between oncology and hematology as each discipline defended its identity.

82 promise may soon be realized in the field of hematology, as hematopoietic stem cell transplants are a

83 ety of Clinical Oncology/American Society of Hematology (ASCO/ASH) recommendations for the use of epo

84 The American Society of Hematology (ASH) and British Committee for Standards in

85 ng antedated that of the American Society of Hematology (ASH) by more than 11 years and Stratton and

86 random sample of the US American Society of Hematology (ASH) membership was surveyed.

87 In 2011, the American Society of Hematology (ASH) published updated guidelines for the ma

88 The American Society of Hematology (ASH) released its first Choosing Wisely((R))

89 The American Society of Hematology (ASH) turns 50 years old in 2008, and we have

90 he Annual Meeting of the American Society of Hematology (ASH), and financial professionals frequently

91 Members Committee of the American Society of Hematology (ASH).(1) The purpose of this initiative is t

92 ology congresses (ie, ASCO 2016 and European Hematology Association 2016) were added to include the m

93 th of Blood in the context of the history of hematology before 1946, emphasizing the American experie

94 from the perspectives of both hepatology and hematology beginning with a brief update on the physiolo

95 nd follow-up measures of health markers (eg, hematology/biopsies).

96 e foremost scholarly journal in the field of hematology, Blood, designed to provide its readership wi

97 col experience of bone marrow failure in the Hematology Branch of the National Heart, Lung, and Blood

98 rm the practice of both benign and malignant hematology, but clinicians must carefully consider these

99 A network of internal medicine and hematology centers across France recruited 198 incident

100 riteria) that was conducted in an outpatient hematology clinic at a US tertiary care hospital from Se

101 otent stem cell (iPSC) technologies into the hematology clinic.

102 sease with respect to clinical presentation, hematology, clinical microbiology, thoracic radiography,

103 ies, which are derived from patients seen in hematology clinics.

104 ectrocardiograms (ECGs); clinical chemistry, hematology, coagulation, and urinalysis; psychomotor fun

105 subjects with respect to clinical chemistry, hematology, coagulation, urinalysis, orthostatic vital s

106 roved by concerted action on the part of the hematology community of the richer countries together wi

107 n, two trials presented at two international hematology congresses (ie, ASCO 2016 and European Hemato

108 The goals of the chapter are to help the hematology consultant work through the differential diag

109 including serum protein electrophoresis and hematology consultation should be considered in the mana

110 be referred for specialized parasitic and/or hematology consultation.

111 loid leukemia (CML), the American Society of Hematology convened an expert panel to review and docume

112 linical Oncology and the American Society of Hematology developed an evidence-based clinical practice

113 applications in the fields of neuroscience, hematology, developmental biology, stem cell biology and

114 Blood chemistries and hematology did not reveal the etiology of the hemorrhage

115 The authors are in the Hematology Division of the Department of Medicine, Brigh

116 e unresolved issues, the American Society of Hematology established a panel to develop a practice gui

117 ologists, reliable patient access to optimal hematology expertise, and optimal patient outcomes.

118 vices are poised to substantially impact the hematology field by providing a high-throughput and rapi

119 induce the changes in serum cholesterol and hematology generally found in copper-deficient animal mo

120 toma Group and German Pediatric Oncology and Hematology Group), and Japan.

121 in German Society of Pediatric Oncology and Hematology Hodgkin Lymphoma Trial 95.

122 g in model organisms along with experimental hematology implicate C/EPBepsilon, RUNX1/AML1, Notch fam

123 Group in 1992 and by the American Society of Hematology in 1996.

124 uacy of dialysis, and serum biochemistry and hematology in patients dialyzed with new or reprocessed

125 The American Society of Hematology is building a collection of case studies to g

126 The field of clinical hematology is no exception.

127 tool over the past two to three decades, in hematology it has primarily been used to investigate are

128 esents an intriguing paradox in the field of hematology known as "Dameshek's riddle." Recent cancer s

129 h use in low-resource settings where central hematology laboratories are not accessible.

130 d cell counts were performed by the clinical hematology laboratory.

131 ts and outpatients who provided blood to the hematology laboratory.

132 CMV-DNA, hematology, liver enzymes, neutralizing antibodies, and

133 lation against data obtained from commercial hematology machines.

134 of patients with germline predisposition to hematology malignancies and will consider applications a

135 by Dutch-Belgium Cooperative Trial Group for Hematology Oncology and the Nordic Myeloma Study Group (

136 AML Cooperative Group and the Dutch-Belgian Hematology Oncology Cooperative group).

137 tory syncytial virus-B (RSV-B) outbreak in a hematology-oncology and stem cell transplant unit.

138 was performed at a referral-based pediatric hematology-oncology clinic and associated inpatient serv

139 We undertook a survey of hematology-oncology fellows training at cancer centers d

140 Factors that influence hematology-oncology fellows' choice of academic medicine

141 udy, which included 1272 platelet-transfused hematology-oncology patients who received 6031 prophylac

142 In hospitalized hematology-oncology patients, culture of blood drawn thr

143 C. krusei was most commonly isolated from hematology-oncology services, where only 76.7% of isolat

144 2009, 4 immunocompromised patients within a hematology-oncology ward exhibited symptoms of pH1N1 inf

145 s (Dutch-Belgian Cooperative Trial Group for Hematology/Oncology [HOVON], UK Medical Research Council

146 disciplinary team with expertise not only in hematology/oncology but also in neurology, neuroradiolog

147 4 HCV infections among patients at the same hematology/oncology clinic.

148 otexafin gadolinium is currently in numerous hematology/oncology clinical trials for use as a single

149 ubjects were advanced cancer patients in the Hematology/Oncology Clinics at the University of Chicago

150 care in outpatient care facilities, such as hematology/oncology clinics.

151 out 18% of immunosuppressed thrombocytopenic hematology/oncology patients and represents a significan

152 ignificant problem for many thrombocytopenic hematology/oncology patients in spite of platelet transf

153 Academic divisions of hematology/oncology seem to have difficulty recruiting a

154 A survey of directors of adult and pediatric hematology/oncology subspecialty training programs in th

155 ent cohort study of patients admitted to our hematology/oncology unit, surveillance cultures revealed

156 tional lymphoma experts representing medical hematology/oncology, radiology, radiation oncology, and

157 RT era, EORTC criteria, developed for use in hematology/oncology, still applied to only half the case

158 atric subspecialty programs in hematology or hematology/oncology.

159 e no significant changes in QoL scores or in hematology or clinical chemistry among treatment groups.

160 There were no changes in hematology or clinical chemistry parameters.

161 nd 47% of pediatric subspecialty programs in hematology or hematology/oncology.

162 ans who were board-certified or -eligible in hematology or medical, pediatric, and gynecologic oncolo

163 ges were found in any clinical chemistry and hematology parameters measured.

164 Clinical chemistry and hematology parameters were determined from terminal bloo

165 samples, and 419 serum samples obtained from hematology patients according to the recommendations.

166 This study screened for mutations in 322 hematology patients classified according to IA status an

167 and serum samples concurrently obtained from hematology patients in a multicenter retrospective anony

168 nce of the serum galactomannan (GM) assay in hematology patients with a potentially low pretest risk

169 Hematology patients with this opportunistic infection re

170 19V infection can be a serious infection for hematology patients with underlying hemolysis or comprom

171 Sites of infection were lungs (28%; 79% in hematology patients), rhinocerebral (25%; 64% in diabeti

172 ently available monotherapy, particularly in hematology patients, has stimulated interest in studying

173 CR assay with blood specimens from high-risk hematology patients.

174 The incidence of IA in high-risk hematology populations is relatively low (<10%), despite

175 h timely reviews, expert opinion on clinical hematology, practice-changing clinical trials, and insig

176 In 1996 the American Society of Hematology published a landmark guidance paper designed

177 In 1996, the American Society of Hematology published a practice guideline for immune thr

178 Although imaging is a vital tool in hematology research, the 3-dimensional architecture of t

179 ntithrombotic therapy and a valuable tool in hematology research.

180 reciable differences in disease progression, hematology, serum biochemistry, virus titers, or lethali

181 fety analyses included physical examination, hematology, serum chemistry, urinalysis, antibody titers

182 mponent, MPC), was measured by the Advia 120 Hematology System as a marker surrogate of platelet acti

183 history, blood analysis using chemistry and hematology tests, and demographic data were collected.

184 In hematology, the clinical disease of mastocytosis is char

185 ments of a new research agenda for geriatric hematology: the exchange of age limits for rigorous frai

186 they have entered common use in experimental hematology to investigate genetic function.

187 ministration invited the American Society of Hematology to participate in the organization and conduc

188 Hematology topics include the use of dabigatran, anticoa

189 luenza A(H1N1) 2009 virus that occurred in a hematology unit in the United Kingdom.

190 rent types of health care settings, except a hematology unit, have been reported.

191 Serum chemistries, hematology, urinalysis, gastrointestinal complications,

192 ficiency at one institution and describe the hematology, virology, and cytokine findings.

193 ycin-resistant enterococci transmission in a hematology ward.

194 duction ratios, monthly blood chemistry, and hematology were also studied during the 12-wk period.

195 Growth and hematology were not affected significantly by iron-zinc

196 Subjects' serum biochemistry and hematology were recorded at screening and at 24-hour fol

197 tering clinical and scientific excellence in hematology will continue as the Society's raison d'etre.

198 This paper, by one of the legends of hematology, William Dameshek, and his colleague Edward M

199 nical development of demethylating agents in hematology, with a focus on azacitidine and decitabine.